{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:27:45Z","timestamp":1794562065221,"version":"4.9.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Americas"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.lana.2026.101621","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T17:36:46Z","timestamp":1788197806000},"page":"101621","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Affordability of new drugs in the Brazilian public health system: a 13-year monitoring analysis of reimbursement decisions based on health technology assessments (2012\u20132024)"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5965-4194","authenticated-orcid":false,"given":"Daniel","family":"da Silva Pereira Curado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7684-0880","authenticated-orcid":false,"given":"Alfredo","family":"Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan Ricardo","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8747-4185","authenticated-orcid":false,"given":"Everton","family":"Nunes da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lana.2026.101621_bib1","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jval.2018.01.001","article-title":"Affordability of health care: a global crisis","volume":"21","author":"Watkins","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.lana.2026.101621_bib2","series-title":"Health at a Glance 2023: OECD Indicators","year":"2023"},{"key":"10.1016\/j.lana.2026.101621_bib3","author":"Vieira"},{"key":"10.1016\/j.lana.2026.101621_bib4","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2025.2043","article-title":"Prices and affordability of essential medicines in 72 low-middle-and high-income markets","volume":"6","author":"Wouters","year":"2025","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.lana.2026.101621_bib5","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12913-025-12207-9","article-title":"The value-for-money assessment and funding arrangements for high-priced drugs in an era of uncertainty: a comparative analysis of national health technology assessment agencies in South Korea, England, Australia, and Canada","volume":"25","author":"Hong","year":"2025","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.lana.2026.101621_bib6","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s41669-021-00311-5","article-title":"Similarities and differences in health technology assessment systems and implications for coverage decisions: evidence from 32 countries","volume":"6","author":"Fontrier","year":"2022","journal-title":"Pharmacoecon Open"},{"key":"10.1016\/j.lana.2026.101621_bib7","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s10198-023-01637-z","article-title":"How can health technology assessment be improved to optimise access to medicines? Results from a Delphi study in Europe: better access to medicines through HTA","volume":"25","author":"Fontrier","year":"2024","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.lana.2026.101621_bib8","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/14737167.2021.1927716","article-title":"Budget impact analysis of medicines: estimated values versus real-world evidence and the implications","volume":"22","author":"Faleiros","year":"2022","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.lana.2026.101621_bib9","article-title":"Health Technologies Assessment: origins, development, and current challenges. In the international and Brazilian scenarios","volume":"36","author":"Novaes","year":"2020","journal-title":"Cad Saude Publica"},{"key":"10.1016\/j.lana.2026.101621_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2021-005429","article-title":"Pay for performance in primary care: the contribution of the Programme for Improving Access and Quality of Primary Care (PMAQ) on avoidable hospitalisations in Brazil, 2009-2018","volume":"6","author":"Russo","year":"2021","journal-title":"BMJ Glob Health"},{"key":"10.1016\/j.lana.2026.101621_bib11","article-title":"Implementation of health technologies in Brazil: analysis of federal guidelines for the public health system","volume":"29","author":"Silva","year":"2024","journal-title":"Cien Saude Colet"},{"key":"10.1016\/j.lana.2026.101621_bib12","doi-asserted-by":"crossref","first-page":"421","DOI":"10.5123\/S1679-49742017000200020","article-title":"Budget impact analysis","volume":"26","author":"Silva","year":"2017","journal-title":"Epidemiol Serv Saude"},{"key":"10.1016\/j.lana.2026.101621_bib13","doi-asserted-by":"crossref","DOI":"10.1590\/s2237-96222025v34e20250122.en","article-title":"Drugs incorporated into the Brazilian Unified Health System: document analysis of methodological decisions in budget impact analyses between 2012 and 2024","volume":"34","author":"Curado","year":"2025","journal-title":"Epidemiol Serv Saude"},{"key":"10.1016\/j.lana.2026.101621_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.856137","article-title":"Social, economic, and regional determinants of mortality in hospitalized patients with COVID-19 in Brazil","volume":"10","author":"Rodrigues","year":"2022","journal-title":"Front Public Health"},{"key":"10.1016\/j.lana.2026.101621_bib15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2147\/CEOR.S338225","article-title":"Economic burden of COVID-19: a systematic review","volume":"14","author":"Richards","year":"2022","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.lana.2026.101621_bib16","article-title":"The effectiveness of COVID-19 vaccines against severe cases and deaths in Brazil from 2021 to 2022: a registry-based study","volume":"20","author":"Santos","year":"2023","journal-title":"Lancet Reg Health Am"},{"key":"10.1016\/j.lana.2026.101621_bib17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","article-title":"Budget impact Analysis\u2014principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force","volume":"17","author":"Sullivan","year":"2014","journal-title":"Value Health"},{"key":"10.1016\/j.lana.2026.101621_bib18","doi-asserted-by":"crossref","first-page":"e2027","DOI":"10.1016\/S2214-109X(25)00319-5","article-title":"Affordability decision rules: a systematic review and framework for categorising budget impact thresholds across health systems","volume":"13","author":"Pichon-Riviere","year":"2025","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.lana.2026.101621_bib19","first-page":"5","article-title":"The reconstruction of the SUS and the fight for rights and democracy","volume":"47","author":"Chioro","year":"2023","journal-title":"Saude Debate"},{"key":"10.1016\/j.lana.2026.101621_bib20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41408-020-0338-x","article-title":"The high cost of prescription drugs: causes and solutions","volume":"10","author":"Vincent Rajkumar","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.lana.2026.101621_bib21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s44162-025-00099-6","article-title":"Rare diseases: a comprehensive literature review and future directions","volume":"4","author":"Chaudhary","year":"2025","journal-title":"J Rare Dis (Berlin)"},{"key":"10.1016\/j.lana.2026.101621_bib22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12992-025-01141-4","article-title":"Pharmaceutical access in Brazil: challenges and opportunities","volume":"21","author":"Ruas","year":"2025","journal-title":"Global Health"},{"key":"10.1016\/j.lana.2026.101621_bib23","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1136\/medethics-2021-107691","article-title":"Should rare diseases get special treatment?","volume":"48","author":"Magalhaes","year":"2022","journal-title":"J Med Ethics"},{"key":"10.1016\/j.lana.2026.101621_bib24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41525-021-00176-x","article-title":"Rare versus common diseases: a false dichotomy in precision medicine","volume":"6","author":"Chung","year":"2021","journal-title":"NPJ Genom Med"},{"key":"10.1016\/j.lana.2026.101621_bib25","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1590\/S0102-311X2012000700002","article-title":"[Guidelines for budget impact analysis of health technologies in Brazil]","volume":"28","author":"Ferreira-Da-Silva","year":"2012","journal-title":"Cad Saude Publica"},{"key":"10.1016\/j.lana.2026.101621_bib26","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1177\/0272989X20954387","article-title":"Estimating downstream budget impacts in implementation research","volume":"40","author":"Wagner","year":"2020","journal-title":"Med Decis Making"},{"key":"10.1016\/j.lana.2026.101621_bib27","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s40258-021-00652-6","article-title":"Systematic literature review of guidelines on budget impact analysis for health technology assessment","volume":"19","author":"Chugh","year":"2021","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.lana.2026.101621_bib28","series-title":"Fiscal sustainability of health systems: how to finance more resilient health systems when money is tight?","year":"2024"},{"key":"10.1016\/j.lana.2026.101621_bib29","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s40273-020-00943-1","article-title":"Integrative review of managed entry agreements: chances and limitations","volume":"38","author":"Zampirolli Dias","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.lana.2026.101621_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1074512","article-title":"Orphan drugs' clinical uncertainty and prices: addressing allocative and technical inefficiencies in orphan drug reimbursement","volume":"14","author":"Eichler","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.lana.2026.101621_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.healthpol.2024.105080","article-title":"HTA criteria adopted in different models of public healthcare systems for orphan drugs: a scoping review","volume":"144","author":"Felippini","year":"2024","journal-title":"Health Policy"},{"key":"10.1016\/j.lana.2026.101621_bib32","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10198-017-0933-3","article-title":"The use of budget impact analysis in the economic evaluation of new medicines in Australia, England, France and the United States: relationship to cost-effectiveness analysis and methodological challenges","volume":"19","author":"Ghabri","year":"2018","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.lana.2026.101621_bib33","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40258-016-0244-3","article-title":"Paucity and inconsistency: a systematic review and critique of budget impact analyses of disease-modifying therapies for multiple sclerosis in the UK and the implications for policy in the UK","volume":"14","author":"Montgomery","year":"2016","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.lana.2026.101621_bib34","series-title":"Budget-Impact Analysis of Health Care Interventions: A Practical Guide","author":"Mauskopf","year":"2017"}],"container-title":["The Lancet Regional Health - Americas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667193X26002516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667193X26002516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:40:41Z","timestamp":1794559241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667193X26002516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":34,"alternative-id":["S2667193X26002516"],"URL":"https:\/\/doi.org\/10.1016\/j.lana.2026.101621","relation":{},"ISSN":["2667-193X"],"issn-type":[{"value":"2667-193X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Affordability of new drugs in the Brazilian public health system: a 13-year monitoring analysis of reimbursement decisions based on health technology assessments (2012\u20132024)","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Americas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lana.2026.101621","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101621"}}